Category: 53838-27-0

Sarnowski, Matthew P.; Kang, Chang Won; Elbatrawi, Yassin M.; Wojtas, Lukasz; Del Valle, Juan R. published an article in 2017, the title of the article was Peptide N-Amination Supports β-Sheet Conformations.Synthetic Route of 53838-27-0 And the article contains the following content:

The conformational heterogeneity of backbone N-substituted peptides limits their ability to adopt stable secondary structures. Herein, we describe a practical synthesis of backbone aminated peptides that readily adopt β-sheet folds. Data derived from model N-amino peptides suggest that extended conformations are stabilized through cooperative steric, electrostatic, and hydrogen-bonding interactions. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Synthetic Route of 53838-27-0

The Article related to backbone aminated peptide beta sheet conformation, foldamers, peptidomimetics, secondary structures, β-hairpins, β-strands, Physical Organic Chemistry: Stereochemistry and Stereochemical Relationships, Including Conformational Inversions and Rotational Isomerization and other aspects.Synthetic Route of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Di Gioia, M. L.; Costanzo, P.; De Nino, A.; Maiuolo, L.; Nardi, M.; Olivito, F.; Procopio, A. published an article in 2017, the title of the article was Simple and efficient Fmoc removal in ionic liquid.Recommanded Product: 53838-27-0 And the article contains the following content:

A mild method for an efficient removal of the fluorenylmethoxycarbonyl (Fmoc) group in ionic liquid was developed. The combination of a weak base such as triethylamine and [Bmim][BF4] made the entire system more efficient for the cleavage at room temperature of various amines e.g. I and amino acid alkyl esters II [R1 = NH2, HNMe; R2 = Me, i-Pr, Ph, etc.; R3 = Me, t-Bu, CH2C6H5] short reaction times. The procedure worked well even in the case of N-Fmoc amino acids bearing acid-sensitive protecting groups and of N-alkylated amino acid alkyl esters, III, e.g. The solvent-free condition provided a complementary method for Fmoc deprotection in solution phase peptide synthesis and modern organic synthesis. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Recommanded Product: 53838-27-0

The Article related to acetyl alkyl ester green preparation, amine amino acid methyl ester preparation acetic anhydride acetylation, amino acid alkyl ester amine deprotection ionic liquid catalyst and other aspects.Recommanded Product: 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 13, 1988, Morimoto, Akira; Noguchi, Noryoshi published a patent.Computed Properties of 53838-27-0 The title of the patent was Preparation of 2-oxoazetidin-1-yl- and 2-oxopyrrolidin-1-yl-5-oxotetrahydrofuran-2-carboxylic acid derivatives as antibacterials. And the patent contained the following:

β-Lactams and 4-butanelactams [I; R1 = NH2, N-bonded organic group; R2 = CO2H or its derivative; n = 1,2] and salts thereof, useful as antibacterials (no data), were prepared Treatment of 2-[(2S)-2-(benzyloxycarbonylamino)-4-hydroxybutyryl]amino-2-(methylthio)glutaric acid 1-4-nitrobenzyl 5-tert-Bu diester (preparation given) with CF3CO2H containing anisole under ice-cooling for 80 min followed by Hg(OAc)2 in DMF at -50 to -20° for 20 min gave 2-[(2S)-2-(benzyloxycarbonylamino)-4-hydroxybutyryl]amino-5-oxotetrahydrofuran-2-carboxylic acid 4-nitrobenzyl ester which was cyclized by treatment with Ph3P and EtO2CN:NCO2Et in THF to give 2-[(3S)-3-(benzyloxycarbonylamino)-2-oxopyrrolidin-1-yl]-5-oxotetrahydrofuran-2-carboxylic acid 4-nitrobenzyl ester. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Computed Properties of 53838-27-0

The Article related to oxoazetidinyloxotetrahydrofurancarboxylate preparation antibacterial, oxopyrrolidinyloxotetrahydrofurancarboxylate preparation antibacterial, beta lactam preparation antibacterial and other aspects.Computed Properties of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On February 14, 2009, Gellerman, Gary; Hazan, Eran; Kovaliov, Marina; Albeck, Amnon; Shatzmiler, Shimon published an article.Related Products of 53838-27-0 The title of the article was Synthesis of orthogonally protected optically pure ketopiperazine, diketopiperazine, ketodiazepane, and 3-aminopyrrolidone building blocks for peptidomimetic combinatorial chemistry. And the article contained the following:

A simple and convenient synthesis of orthogonally protected multi-tethered, optically pure 2-ketopiperazine, diketopiperazine, 2-ketodiazepane and 3-aminopyrrolidone scaffolds for Fmoc combinatorial chem. has been developed. It utilizes accessible chiral amino acid precursors, sequentially applying reductive alkylation, dipeptide coupling and regioselective ring formation as key steps. These scaffolds are expansion of our “pool of privileged building blocks” and can introduce valuable drug-like properties in three independent directions to any medicinally relevant piperazine-, diazepane- and pyrrolidone-based motif by “around-the-scaffold” drug optimization. The synthetic routes reported in this work are general and applicable for the preparation of a diverse library of scaffolds, controlling chirality, arm position and length as well as the nature of functional moieties at the arms for further diversification in three independent directions. In addition, these building blocks have a wide application scope in managing fast and efficient multi-cyclic optimization processes in the combinatorial chem. and drug design fields. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Related Products of 53838-27-0

The Article related to ketopiperazine diketopiperazine ketodiazepane aminopyrrolidone protected enantiopure preparation peptidomimetic, amino acid reductive alkylation dipeptide coupling regioselective cyclization and other aspects.Related Products of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On November 6, 2003, Arrhenius, Thomas; Cheng, Jie-fei; Huang, Yujin; Nadzan, Alex M. published a patent.Reference of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the patent was Preparation of azolylhexafluoropropanols and related compounds as liver X receptor (LXR) modulators. And the patent contained the following:

A method for modulation of liver X receptor comprises administration of WC(X)(AY)CF2Z [W = specified (substituted) 5-6 membered (aromatic) heterocyclyl, alkynyl; X = H, CF2Z, CF3; XY forms a double bond when A = O; Y = H; Z = F, Br, Cl, iodo, CF3; A = O, S, imino]. Thus, powd. 4Å mol. sieves, N-(pyridin-4-ylmethyl)-1,3-thiazol-2-amine (preparation given), and hexafluoroacetone trihydrate were heated in PhH at 80° for 24 h to give 1,1,1,3,3,3-hexafluoro-2-[2-[(pyridin-4-ylmethyl)amino]-1,3-thiazol-5-yl]propan-2-ol. The latter was refluxed with isonicotinic anhydride in dioxane at 100° for 2 h to give N-(pyridin-4-ylmethyl)-N-[5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-1,3-thiazol-2-yl]pyridine-4-carboxamide. This at 10 μM gave 2.49-fold induction of ABCA1 gene in THP-1 cells vs. DMSO controls. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Reference of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to azolylhexafluoropropanol preparation liver x receptor lxr modulator, thiazolylhexafluoropropanol preparation liver x receptor lxr modulator, isoxazolylhexafluoropropanol preparation liver x receptor lxr modulator and other aspects.Reference of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 12, 2002, Bryant, Judi A.; Buckman, Brad O.; Islam, Imadul; Mohan, Raju; Morrissey, Michael M.; Wei, Guo Pin; Xu, Wei; Yuang, Shendong published a patent.Safety of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the patent was Preparation of 2-[(piperazinocarbonylmethyl)aminocarbonyl]quinolines as platelet adenosine diphosphate receptor antagonists. And the patent contained the following:

The title compounds [I; a, b = 1-4; A = CH, N; R1 = H, alkyl, aryl, etc.; R2 = H, alkyl, aryl, etc.; R3 = H, alkyl, OH, etc.; R4 = H, alkyl, alkoxy, etc.; R5 = H, alkyl, hydroxyalkyl, etc.; R6 = NR7CO, CONR7; R7 = H, alkyl, carboxyalkyl, alkoxycarbonylalkyl], useful as inhibitors of platelet aggregation and thrombus formation, were prepared and formulated. Thus, amidation of 7-methyl-4-hydroxy-2-carboxyquinoline with 4-ethoxycarbonyl-1-[1-amino-3-(1,1-dimethylethoxycarbonyl)propyl]carbonylpiperazine (preparation of both reactants given) afforded 68% I [R1 = CO2Et; R2 = tert-BuOCOCH2CH2; R3 = OH; R4 = 7-Me; R5 = H; R6 = NHCO; A = N]. The compounds I demonstrated their ability to inhibit the binding of [33P]-2-methylthio-ADP binding to the human platelet ADP receptor and the rat platelet ADP receptor. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Safety of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to piperazinocarbonylmethylaminocarbonyl quinoline preparation platelet adenosine diphosphate receptor antagonist antithrombotic, platelet aggregation inhibitor piperazinocarbonylmethylaminocarbonyl quinoline preparation and other aspects.Safety of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On November 2, 2006, Caroff, Eva; Fretz, Heinz; Hilpert, Kurt; Houille, Olivier; Hubler, Francis; Meyer, Emmanuel published a patent.Category: esters-buliding-blocks The title of the patent was Preparation of N-(4-pyrimidinylcarbonyl) amino acid piperazides and their use as P2Y12 receptor antagonists. And the patent contained the following:

The invention relates to the preparation of title compounds I [R1 = (un)substituted Ph; W = a bond and R2 = CN, halo/alkoxy/heterocyclyl/cyclo/cycloalkyl/alkyl, hetero/ary/, heterocyclyl, (partially) saturated heterocyclyl; (un)substituted hydroxyalkyl; W = CH2 and R2 = NR7R8, SR9, SO2R10; W = O, S, and R2 = alkoxycarbonyl/carboxy/hydroxy/alkoxy/heterocyclyl/cyclo/ar/heteroaryl/alkyl, hetero/aryl; W = NH and derivatives and R2 = H, dialkylamino/alkoxycarbonyl/hydroxy/alkoxy/cyclo/heterocyclyl/cycloalkyl/ar/diphenyl/heteroaryl/alkyl, aryl, 2-phenylcyclopropyl, COR11, SO2R12, (un)substituted carboxyalkyl; W = CH:CH and R2 = hydroxy/alkoxy/alkyl alkoxycarbonyl, Ph, or CONR13R14; ; or W = CC and R2 = H, hydroxy/alkoxy/alkyl; or W = CO and R2 = alkyl; W = NR3 and NR2R3 = 4-7 membered heterocyclyl; or W = NR3 and NR2R3 = (un)substituted imidazoyl, pyrazolyl, 1,2,3-triazolyl, etc.; R5a, R5b = independently H, Me; R3 = H, alkyl; R7 aryl/alkyl; or NR7R8 = (un)substituted 4-7 membered heterocyclyl; R9 = cycloalkyl, aryl; R10 = cyclo/alkyl, aryl; R11 = alkoxy/alkyl, hetero/aryl, etc.; R12 = alkyl, aryl; R13, R14 = independently alkyl; X = CO and R6 = cyclo/alkyl, alk(ynyl)oxy, aryloxy, aralkoxy, hetero/aryl,aralkyl or NH2 and derivatives; or X = SO2 and R6 = alkyl; Y = a bond and Z = H, aryl substituted by carboxyalkoxy; or Y = alkoxy/Ph/alkoxyphenyl/alkylene, alkoxyphenylene and Z = H, OH, NH2, CO2H, tetrazolyl, CONH2, COOR17, NHCOR17, NHSO2R17; R17 = alkyl], as P2Y12 receptor antagonists. The invention also relates to the use of pyrimidines I and their stereoisomers, salts, solvent complexes and morphol. forms, in the treatment and/or prevention of peripheral vascular, visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases (no data) or conditions associated with platelet aggregation (no data), particularly thrombosis (no data). Thus, a multi-step synthesis starting from Z-L-Glu(Ot-Bu)-OH (Z = benzyloxycarbonyl) and 1-ethoxycarbonylpiperazine was given for amino acid piperazide II. In a P2Y12 binding assay, II had an IC50 = 117 nM. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Category: esters-buliding-blocks

The Article related to amino acid piperazide preparation p2y12 receptor antagonist thrombosis, platelet aggregation pyrimidinylcarbonyl amino acid piperazide preparation, piperazino carbonylmethylaminocarbonylpyrimidine preparation p2y12 antagonist and other aspects.Category: esters-buliding-blocks

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On February 9, 2012, Manoharan, Muthiah; Rajeev, Kallanthottathil G.; Yamada, Takeshi; Butler, David; Jayaprakash, K. Narayanannair; Jayraman, Muthusamy; Matsuda, Shigeo; Pandey, Rajendra K.; Peng, Chang Geng published a patent.Computed Properties of 53838-27-0 The title of the patent was Preparation of monomers and oligonucleotides comprising triazolyl cycloaddition adducts via click chemical for treating various disorders and diseases. And the patent contained the following:

Oligonucleotides monomers I were prepared and incorporated into RNA, wherein X is O, S, NRN, CRP2; B is independently H, nucleobase, triazole; NH-C(O)-O-C(CH2B1)3, NH-C(O)-NH-C(CH2B1)3; where B1 is halogen, mesylate, N3, CN, triazole, tetrazole; R1-R5 are each independently H, OR6, F, N(RN)2, N3, CN, -J-linker-N3, -J-linker-CN, -J-linker-C-R8, -J-linker-cycloalkyne, -J-cycloalkylidene-linker, -J-heterocyclyl-linker; J is independently absent, O, S, NRN, OC(O)NH, NHC(O)O,C(O)NH, NHC(O), NHSO, NHSO2, NHSO2NH, OC(O), C(O)O, OC(O)O, NHC(O)NH, NHC(S)-NH, OC(S)-NH, O-N=CH, OP(N(RN)2)O, or OP(N(RN)2); R6 is independently H, hydroxy protecting group, alkyl, aryl, cycloalkyl, aralkyl, alkenyl, heteroaryl, polyethylene glycol, phosphate, phosphonate, phosphonothioate, phosphorothiolothionate, phosphodiester, phosphoramidite, solid support, nucleoside, oligonucleotide; RN is independently H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, aralkyl, heteroaryl, amino protecting group; RP is independently H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl. Thus, glycoside II was prepared and used in synthesis of DNA duplexes synthesis. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immuno-deficiencies and immunosuppression. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Computed Properties of 53838-27-0

The Article related to lipid azide preparation click alkyne rna preparation antiviral human, antiviral parasiticide antitumor immunosuppression autoimmune rna dna duplex preparation, click azide alkyne triazole nucleotide preparation sirna dna peptide and other aspects.Computed Properties of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 12, 1998, Picard, Joseph Armand; Sliskovic, Drago Robert published a patent.Computed Properties of 53838-27-0 The title of the patent was Preparation of dibenzofuransulfonyl and related amino acids for inhibition of matrix metalloproteinases. And the patent contained the following:

Heterocyclyl sulfonyl amino acids I (R = unnatural amino acid; X = O, S, SO, SO2, CO, NH, alkyl- or alkylphenylimino; R1, R2 = H, alkyl, Ph, NO2, halo, alkoxy, CN, etc.) or their pharmaceutically acceptable salts, esters, amides, and prodrugs were prepared as matrix metalloproteinases inhibitors. Thus, 6-[2-(4-chlorophenoxy)-2-methylpropionylamino]-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid, prepared by acylation of 6-amino-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid Me ester hydrobromide, showed IC50 >100 μM against MMP-1 and MMP-7. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Computed Properties of 53838-27-0

The Article related to amino acid dibenzofuransulfonyl dibenzothiophenesulfonyl preparation activity, dibenzofuransulfonyl amino acid preparation inhibitor metalloproteinase, dibenzothiophenesulfonyl amino acid preparation inhibitor metalloproteinase and other aspects.Computed Properties of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 10, 2003, Dhar, T. G. Murali; Potin, Dominique; Maillet, Magaili Jeannine Blandine; Launay, Michele; Nicolai, Eric Antoine; Iwanowicz, Edwin J. published a patent.Application In Synthesis of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the patent was Preparation of spiro-hydantoin compounds useful as anti-inflammatory agents. And the patent contained the following:

Title compounds I [L and K independently = O or S; X = N or CR3; Ar = aryl or heteroaryl; G is attached via T or M with provision when attached to C, G = bond, O, N, S, (un)substituted alkylene, bivalent alkoxy, etc., when G is attached to N, G = bond, (un)substituted alkylene, bivalent acyl or alkoxycarbonyl, and a bivalent alkoxy, alkylthio, aminoalkyl, sulfonyl, or sulfonamidyl wherein each of said G groups have at least one carbon atom attached to ring A; T = T1 when G-Ar is attached to T, and T2 when G-Ar is attached to M; M = M1 when G-Ar is attached to M, and M2 when G-Ar is attached to T; T1 and M1 = N, CR5; T2 and M2 = O, S, -N=, SO2, etc.; R1, R2, and R3 independently = H, halo, (un)substituted-alkyl, -alkenyl, NO2, etc.; R4 = H, (un)substituted alkyl, OH, NH2, alkoxy, etc.; R5 = H, (un)substituted alkyl, halo, CN, OH, etc.; J = O, S, -N=, SO2, substituted N, etc.; ], and pharmaceutically-acceptable salts, hydrates,enantiomers, and diastereomers, and prodrugs thereof, (I) are prepared and disclosed as inhibitors of LFA-1/ICAM and as anti-inflammatory agents. Thus, II was prepared by base catalyzed cyclization of 1-bromo-4-(1,4-dibromobutyl)benzene (preparation given) with 3-(3,5-dichlorophenyl)-1-methylimidazolidine-2,4-dione. Assays indicated I have a measurable level of activity as inhibitors of LFA-1 and/or ICAM (no data). The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Application In Synthesis of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to hydantoin spiro preparation antiinflammatory nsaid lfa1 icam, spiro pyrrole imidazolinedione preparation, lymphocyte function associated antigen inhibitor spirohydantoin, intercellular adhesion mol inhibitor spirohydantoin and other aspects.Application In Synthesis of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics